NCT06568783View on ClinicalTrials.gov

Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2028

Conditions
Refractory Dermatomyostitis
Interventions
DRUG

[18F]-FAPI-74

\[18F\]-FAPI-74 7 mCi ± 20% administered intravenously.

Trial Locations (1)

94304

Stanford University, Stanford

All Listed Sponsors
lead

Farshad Moradi

OTHER